for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vertex Pharmaceuticals Incorporated

VRTX.O

Latest Trade

218.10USD

Change

1.60(+0.74%)

Volume

2,033,259

Today's Range

215.84

 - 

220.54

52 Week Range

197.47

 - 

306.08

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
216.50
Open
217.87
Volume
2,033,259
3M AVG Volume
42.52
Today's High
220.54
Today's Low
215.84
52 Week High
306.08
52 Week Low
197.47
Shares Out (MIL)
260.17
Market Cap (MIL)
56,298.20
Forward P/E
20.93
Dividend (Yield %)
--

Next Event

Q4 2020 Vertex Pharmaceuticals Inc Earnings Release

Latest Developments

更多

Vertex Recommends Rejection Of ‘Mini-Tender’ Offer From TRC Capital Investment

Vertex Pharmaceuticals Posts Qtrly Earnings Per Share $2.53

Vertex Pharmaceuticals- On September 18, Co Entered Into A Credit Agreement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Industry

Biotechnology & Drugs

Contact Info

50 Northern Ave

BOSTON, MA

02210-1862

United States

+1.617.3416393

https://www.vrtx.com/

Executive Leadership

Jeffrey M. Leiden

Executive Chairman of the Board

Reshma Kewalramani

President, Chief Executive Officer, Director

Charles F. Wagner

Chief Financial Officer, Executive Vice President

Michael J. Parini

Executive Vice President, Chief Legal and Administrative Officer

David Altshuler

Executive Vice President - Global Research, Chief Scientific Officer

Key Stats

1.93 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

2.2K

2018

3.0K

2019

4.0K

2020(E)

6.1K
EPS (USD)

2017

1.950

2018

4.080

2019

5.330

2020(E)

10.325
Price To Earnings (TTM)
21.19
Price To Sales (TTM)
9.40
Price To Book (MRQ)
6.93
Price To Cash Flow (TTM)
20.13
Total Debt To Equity (MRQ)
6.72
LT Debt To Equity (MRQ)
6.72
Return on Investment (TTM)
34.89
Return on Equity (TTM)
28.60

Latest News

Latest News

EU drug regulator endorses Vertex's triple-combo cystic fibrosis treatment

Europe's health regulator said on Friday its panel has recommended approval of Vertex Pharmaceuticals' triple-combination treatment for cystic fibrosis (CF), a deadly disease that causes build-up of thick mucus in some parts of the body.

BRIEF-Crispr Therapeutics And Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted To Ctx001™ For The Treatment Of Severe Hemoglobinopathies

* CRISPR THERAPEUTICS AND VERTEX PHARMACEUTICALS ANNOUNCE FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION GRANTED TO CTX001™ FOR THE TREATMENT OF SEVERE HEMOGLOBINOPATHIES Source text for Eikon: Further company coverage:

Drugmaker Vertex to delay new clinical studies due to coronavirus

U.S. drugmaker Vertex Pharmaceuticals Inc said on Friday it would delay starting some clinical trials and temporarily pause enrolment in some studies, as it looks to free up hospitals to deal with the coronavirus outbreak.

BRIEF-CRISPR Therapeutics And Vertex Announce Data From Two Patients Treated With Gene-Editing Therapy CTX001

* CRISPR THERAPEUTICS AND VERTEX ANNOUNCE POSITIVE SAFETY AND EFFICACY DATA FROM FIRST TWO PATIENTS TREATED WITH INVESTIGATIONAL CRISPR/CAS9 GENE-EDITING THERAPY CTX001 FOR SEVERE HEMOGLOBINOPATHIES

UPDATE 1-Vertex deal with Wales expands cystic fibrosis treatment coverage to all of UK

Vertex Pharmaceuticals Inc's drugs for lung condition cystic fibrosis will now be available to patients across the UK after the company reached a pricing deal with Wales on Wednesday.

Vertex reaches deal with Wales for cystic fibrosis treatment

Vertex Pharmaceuticals Inc said on Wednesday cystic fibrosis patients in Wales would get access to the company's life-extending drugs following an agreement with the state-funded health service.

UPDATE 1-Vertex cystic fibrosis drug to be available in England after pricing deal

Cystic fibrosis patients in England will have access to life-extending drugs after the state-funded health service said it had agreed a pricing deal with manufacturer Vertex Pharmaceuticals.

Cystic fibrosis drug to be available in England after pricing deal

Cystic fibrosis patients in England will have access to life-extending drugs after the state-funded health service said it had agreed a pricing deal with manufacturer Vertex Pharmaceuticals.

UPDATE 2-Vertex prices cystic fibrosis combo treatment at $311,000/yr

Vertex Pharmaceuticals Inc has priced its three-drug combination for cystic fibrosis (CF) at $311,503 per year, after winning early U.S. approval on Monday.

FDA approves Vertex Pharma's combo treatment for cystic fibrosis

The U.S. Food and Drug Administration approved Vertex Pharmaceuticals Inc's combination treatment for a rare condition called cystic fibrosis, the agency said on Monday.

Vertex to buy cell therapy developer Semma for $950 mln

Vertex Pharmaceuticals Inc said on Tuesday it would buy privately held Semma Therapeutics for $950 million in cash to develop stem-cell based treatments for diabetes.

Vertex Pharmaceuticals expands into Duchenne gene therapy with new deals

Vertex Pharmaceuticals Inc said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190606:nBw4wRKsa on Thursday it would acquire privately held Exonics Therapeutics for an upfront payment of $245 million and potential milestone payments...

Vertex to file for approval of cystic fibrosis therapy in 2019

Vertex Pharmaceuticals Inc said on Thursday it will apply for regulatory approval later this year for its triple combination of drugs to treat life-shortening genetic condition cystic fibrosis.

BRIEF-Cincor Pharma Closes $50 Mln Series A Financing

* CINCOR PHARMA IN-LICENSES ALDOSTERONE SYNTHASE INHIBITOR, CIN-107, AND CLOSES $50 MILLION SERIES A FINANCING

BRIEF-Crispr Therapeutics And Vertex Announce FDA Fast Track Designation For CTX001 For Treatment Of Beta Thalassemia

* CRISPR THERAPEUTICS AND VERTEX ANNOUNCE FDA FAST TRACK DESIGNATION FOR CTX001 FOR THE TREATMENT OF BETA THALASSEMIA Source text for Eikon: Further company coverage:

UPDATE 2-Vertex cystic fibrosis triple combo therapy succeeds in important trials

Vertex Pharmaceuticals Inc on Wednesday said its triple-combination treatment for cystic fibrosis led to significant lung function improvement in two late-stage studies, paving the way for a therapy that could eventually address 90 percent of people with the life-shortening...

UPDATE 1-Vertex Pharma boots out COO for "personal behavior" violations

Vertex Pharmaceuticals Inc said on Wednesday it had terminated the employment of its chief operating officer and interim chief financial officer, Ian Smith, citing "personal behavior" that violated its code of conduct.

Vertex Pharma terminates interim CFO's employment for code violations

Vertex Pharmaceuticals Inc said on Wednesday it had terminated the employment of its chief operating officer and interim chief financial officer, Ian Smith, citing personal behavior that violated its code of conduct.

REFILE-Vertex posts positive data from cystic fibrosis triple combo trials

Vertex Pharmaceuticals Inc said on Tuesday that its triple combination therapy showed significant improvement in lung function in patients with cystic fibrosis (CF) in two late-stage clinical studies, sending its shares up 5 percent.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up